Go East  by Peck-Radosavljevic, Markus
EditorialGo East
Markus Peck-Radosavljevic
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, AKH & Medical University of Vienna, AustriaDear friends of EASL,
More than 20 years ago we witnessed several big changes to
the geopolitical situation in Europe. It started with the disintegra-
tion in South Eastern Europe with the state formally known as
Yugoslavia breaking up into several independent states. And it
continued with the fall of the iron curtain and the break-up of
the USSR into Russia and a larger number of countries including
the Baltic States and the CIS countries. The opening of the borders
of many of those countries lead to rapid economic changes that
preceded the political integration of several Eastern European
Countries into the European Union in 2004, in 2007 and ﬁnally
in 2013. Despite the dramatic economic and political changes
in many of the Eastern Countries, healthcare in many of those
has not improved at the same pace. This may be related to the
fact that health is not the ﬁrst priority area when big social and
political changes are happening. But this may also be due to
the fact that health at least within the European Union remains
a Member State issue that is much more dependent on local reg-
ulations and custom than the more general rules of the Union
would allow for in the area of economy or ﬁnance. And several
of the new Member States were particularly affected by the
ﬁnancial crises of 2008 and are still suffering from its aftermath,
leaving less money for health related issues and innovation in
healthcare.
These changes within Europe and the neighboring countries
have also had a profound effect on professional medical associa-
tions like EASL. For many years we have been reaching out to our
fellow hepatologists, gastroenterologists, and infectious disease
specialists from neighboring countries to invite and join our com-
munity and to integrate into the European framework of liver
specialists through participation in the International Liver Con-
gress and many other educational activities. This outreach was
rewarded with success: EASL membership statistics show a steep
increase in membership for those countries with the Top 5 being
Romania, Turkey, Russia, Bulgaria, and Croatia with increases of
more than 400% in some of these countries. Likewise, we are wit-
nessing a good increase in participation at the educational and
scientiﬁc sessions at the International Liver Congress from year
to year from our Eastern and South Eastern neighbors. And even
the active participation in our meeting as measured by the sub-
mission of abstracts from these countries has improved a lot. AtJournal of Hepatology 20
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Open access under CC BY-NC-ND license.least two of these countries can now be found amongst the top
20 submitters of abstracts.
At the same time there are still some quite signiﬁcant gaps in
knowledge about liver disease, training in the management of
liver disease, and research training in liver disease in many of
those countries beyond the recognized centers of excellence.
When EASL was compiling the data for its White paper on the
burden of liver disease in Europe [1], a lot of blanks remained
on the map, particularly relating to published data outside the
ﬁeld of viral hepatitis. And when reviewing the applications for
the EASL fellowship program in the past two years, we noticed
that very few came from Eastern European applicants. EASL rec-
ognizes that waiting for things to improve by themselves might
not be enough and is determined to play a much more active role
to homogenize expertise and training in all of Europe and its
neighboring countries. In order to do this, the EASL business plan
for the next few years should include three focus areas:
Clinical training in many countries is already at a high stan-
dard in a few centers of excellence but a similar standard cannot
be achieved in many smaller centers in the region. Improving this
situation would require a joint effort of local professional medical
societies together with EASL to organize local trainings at a
higher standard because many of the physicians in the more
remote areas will not have the opportunity to frequently travel
to EASL events.
We need to foster interest in clinical research and provide
training in clinical research beyond centers of excellence, which
are already integrated into the international clinical trials land-
scape. In particular, we should try to raise interest in conducting
local investigator initiated trials that will help to document stan-
dards and improve the quality of care in those countries.
And last but not least we need to provide research training in
translational research: participation in the young investigator
master class and engagement with the EASL fellowship program
including Entry Level, Sheila Sherlock, and Physician Scientist Fel-
lowships should be an integral part of achieving this goal.
But EASL also recognizes that developing a fruitful strategy to
advance towards those goals cannot be achieved by the EASL gov-
erning board on its own. We need to integrate scientists and edu-
cators from Eastern Europe and neighboring countries into an
advisory body that will provide us with the necessary local
knowledge to make use of our resources in the most efﬁcient
way.
So while in the 19th century the right thing to do for gold-dig-
gers was to go West, in the 21st century the call is out for hepa-
tologists to go East: this is not about ﬁnding gold, it is about14 vol. 60 j 4–5
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getting the best of patient care and research into a large geo-
graphic region with a high burden of chronic liver disease and a
large unmet need to take care of it.Journal of Hepatology 2Reference
[1] Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The
burden of liver disease in Europe: a review of available epidemiological data. J
Hepatol 2013;58:593–608.014 vol. 60 j 4–5 5
